Institutional members access full text with Ovid®

Share this article on:

The Prevalence of Microscopic Hematuria in Women With Pelvic Organ Prolapse

Shalom, Dara F. MD*; Lin, Stephanie N. MD†; St. Louis, Sarah MD‡; Lind, Lawrence R. MD*; Winkler, Harvey A. MD*

Female Pelvic Medicine & Reconstructive Surgery: November/December 2011 - Volume 17 - Issue 6 - pp 290-292
doi: 10.1097/SPV.0b013e3182357afb
Original Articles
Journal Club

Objective: The objective of the study was to determine the prevalence of microscopic hematuria (MH) in women with pelvic organ prolapse.

Study Design: Data of all patients presenting to a urogynecologic center with pelvic organ prolapse between 2008 and 2010 were reviewed. Microscopic hematuria was defined as 3 or more red blood cells per high-power field on at least 2 urinalysis specimens with negative cultures. Exclusion criteria included age younger than 40 years, presence of gross hematuria, menses, or urologic disease. Statistical analysis was performed using JMP 4.0.4 (SAS Institute, Cary, NC).

Results: The population consisted of 572 women aged 40 to 96 years. Fifty-five patients (9.6%) met the criteria for MH, and 126 (22%) had 3 or more red blood cells per high-power field on 1 urinalysis. No cases of urologic malignancy were diagnosed on further workup. All patients with microhematuria had cystoceles on examination.

Conclusions: Our findings suggest that the prevalence of MH is increased in women with pelvic organ prolapse.

From the *Division of Urogynecology and Pelvic Reconstructive Surgery, North Shore University Hospital/LIJ, Manhasset; †Obstetrics and Gynecology, New York Presbyterian Hospital Weill Cornell Medical Center, New York; and ‡Obstetrics and Gynecology, Long Island Jewish Medical Center, New Hyde Park, NY.

Reprints: Dara F. Shalom, MD, 865 Northern Blvd, Suite 202, Great Neck, NY 11021. E-mail: dshalom@nshs.edu.

No financial support was provided for this study.

This study was conducted in Great Neck and Manhasset, NY.

The authors declare that they have nothing to disclose.

© 2011 by Wolters Kluwer Health | Lippincott Williams & Wilkins